Alexion Pharma (ALXN) Receives EC Approval for Kanuma for Long-Term ERT in LAL-D Patients
Tweet Send to a Friend
Alexion Pharma (NASDAQ: ALXN) announced that the European Commission (EC) has approved Kanuma™ (sebelipase alfa) for long-term enzyme replacement therapy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
